Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Changes Following Trabectedin in Sarcoma
NCT03397186Phase 2Withdrawn
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2018
- Primary completion
- Jan 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trabectedin in soft tissue sarcoma (STS), sponsored by Fred Hutchinson Cancer Center. Planned start Jun 2018; status: withdrawn.
02
Drugs
trabectedin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03397186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03397186.